GSK posts Phase 3b results for Bexsero booster; registers new bioavailability and UC trials

GSK's registry activity for the week of November 4, 2026 is headlined by results from a completed Phase 3b vaccine study, plus two newly posted Phase 1 trials and four previously listed studies spanning COPD, asthma, oncology, and infectious disease.

• A completed Phase 3b study (NCT06995430) posted results on a booster dose of the meningococcal group B vaccine rMenB+OMV NZ, known as Bexsero, given to participants aged 10 to 20 who had been first vaccinated with rMenB+OMV NZ as infants¹. The trial enrolled 312 participants, with the study reaching actual primary completion.¹ The primary outcome measured human serum bactericidal assay titers expressed as geometric mean titers against each MenB indicator strain, including fHbp, NadA, NHBA and PorA, at Day 31.¹
• A new Phase 1 trial (NCT07712393) will compare how two different formulations of the study medicine GSK5784283 move through the body over time in healthy adults.² The study is listed as active not recruiting, with enrollment of 24 participants across test and reference formulation arms² at one site in Austin, Texas.
• A new Phase 1b sub-study (NCT07747480) will test aletekitug, an anti-IL-18 agent, for safety and tolerability in participants with moderately to severely active ulcerative colitis.³ It is recruiting, with estimated enrollment of 16 participants³ at one site in Oxford, United Kingdom.
• "ALARMONY" (NCT07915791) remains a Phase 2, randomized, placebo-controlled trial testing two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care⁴ in moderate to severe COPD, not yet recruiting with an estimated start of November 9, 2026 and planned enrollment of 279 participants.
• The Phase 3 asthma trial comparing FF/UMEC/VI with FF/VI in 12-17-year-olds (NCT05757102) remains active not recruiting, evaluating the effects of Fluticasone Furoate/Umeclidinium/Vilanterol on lung function compared with FF/VI after 24 weeks of treatment,⁵ with enrollment of 138 participants.
• "BEHOLD-Ovarian03" (NCT07694427) remains a recruiting Phase 3 trial testing mocertatug rezetecan with or without bevacizumab against active observation as maintenance therapy in newly diagnosed advanced ovarian cancer, sponsored by GSK with collaborators ENGOT, GOG and APGOT,⁶ and planned enrollment of 720 participants.⁶
• "B-Ensure" (NCT07908459) remains a Phase 4 study, not yet recruiting, following adults with chronic hepatitis B who previously received 24 weeks of Bepirovirsen treatment and achieved hepatitis B surface antigen levels less than or equal to 100 IU/mL at Week 72 without achieving functional cure,⁷ with an estimated start of December 3, 2026.